NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

I may be mistaken, but I don't believe the Journal prevents NWBO from issuing TLD, I believe it's a decision made by the company and today's presentation pretty much defines what they ought to be saying.

While I still do not understand why more than 50 people do not appear to be alive based on the K-M plots, and I believe that contradicts what Drs. Liau and Ashkan have said when discussing the Top 100, it's clear that there is a tremendous survival benefit long term.

In most trials that I've been aware of approval could be achieved with a 10 to 20% improvement on the SOC. Overall survival is the gold standard for judging outcomes and we're more than doubling the long term survival. I believe we'll get more information in the Journal, but while a TLD statement may need to say secondary end points weren't achieved due to pseudoprogression being taken as progression, the OS data is clearly a marked improvement and certainly worthy of approval without additional testing being required.

Gary